Form 4: Director R. Michael Carruthers Receives Stock Options

OnKure Therapeutics director R. Michael Carruthers was granted 7,650 stock options as part of standard equity compensation.

Summary

• Director R. Michael Carruthers received a grant of 7,650 stock options for Class A Common Stock.
• The options have an exercise price of $4.30 per share.
• The grant date for the transaction was June 4, 2026.
• The options are scheduled to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director continuing as a service provider through the vesting date.

Future Outlook

The options vest on the earlier of June 4, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of a one-year cliff or annual meeting-based vesting is a standard retention mechanism for board members.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Trading, Stock Options, Director Compensation